肺癌分期:消融治疗与肺段切除术时代的最新技术
肺癌筛查与影像学进步使早期肺癌比例增加,治疗从解剖性肺叶切除扩展至肺段切除和SABR等保留器官方式。本文综述拟接受肺段切除或消融患者的当前分期方法,强调准确分期对最大化根治机会至关重要,并提出待研究问题。
要点
- 早期肺癌比例增加,肺段切除与SABR等保留器官治疗正在应用或研究中。
- 新治疗方式以降低并发症为代价,可能牺牲晚期病变的疗效。
- 拟行肺段切除或消融者须准确分期以最大化根治治疗潜力。
核心结论
- 拟接受肺段切除或消融的肺癌患者需准确分期,以最大化根治治疗的可能性。
研究设计与样本
- 本文为综述,回顾拟接受肺段切除或消融患者的当前分期方法。
主要发现
- 肺癌筛查与影像学进步预期将增加早期肺癌的诊断比例。
- 解剖性肺叶切除历来是标准治疗,现有多种手术与非手术治疗局部病变的方式在应用或研究中。
- 新方式理论上以降低并发症换取晚期病变疗效的降低。
临床怎么用
- 对拟行肺段切除或SABR的患者应进行准确分期,以评估根治治疗的可能性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Implementation of lung cancer screening and improvements in imaging are expected to increase the proportion of lung cancer diagnosed at an early stage. The standard of care has historically been anatomic lobectomy; however, there is now an array of surgical and non-surgical approaches for management of local disease either in active use or under investigation. By their nature, these new modalities offer a theoretical trade-off of reduced morbidity in exchange for reduced efficacy in the setting of advanced disease. It is therefore critical that patients being considered for these approaches (e.g. surgical segmentectomy and SABR) be accurately staged to maximize the potential for definitive treatment. In this article, we will review current approaches to the staging of patients being considered for segmentectomy or ablation. This will serve as a foundation to highlight important questions deserving further investigation.
引用
- Gregor A, Inage T, Hwangbo B, et al. Lung cancer staging: State of the art in the era of ablative therapies and surgical segmentectomy. Respirology. 2020. PMID: 32323421. doi:10.1111/resp.13827
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。